RxDoctor Payments Data

Kendra Kay, MD

Internal Medicine · Columbia, MDNPI 1417923905

Payments from drug & device makers

$2,192in general payments, 2019–2025

Across 131 payments — averaging $16.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$382
  • Novo Nordisk$289
  • Astellas Pharma US Inc$250
  • AstraZeneca$175
  • Lilly USA, LLC$165
  • Takeda Pharmaceuticals U.S.A., Inc.$150
  • plus $782 from 18 others

What the payments were for

  • Food & beverage$2,192100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,192 in reported general payments places this provider in the 80th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$124,513
Medicare patients
218
Services billed
1,849

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide66$85,680
TrulicityDulaglutide61$83,508
JardianceEmpagliflozin52$67,484
EliquisApixaban43$48,474
Nurtec OdtRimegepant Sulfate15$41,779
LinzessLinaclotide41$34,557
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$26,622
XareltoRivaroxaban19$21,648
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$12,258
JanumetSitagliptin Phos/Metformin Hcl11$9,013
Combivent RespimatIpratropium/Albuterol Sulfate15$7,963
Bromocriptine Mesylate12$6,207
Advair HfaFluticasone Propion/Salmeterol15$3,642
Aripiprazole16$3,140
Atorvastatin Calcium245$2,279

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$79$90,25358 claims
Novo NordiskOzempic$289$85,68066 claims
Lilly USA, LLCTrulicity$165$83,50861 claims
Boehringer IngelheimJardiance, Combivent Respimat$117$75,44767 claims
AbbVieLinzess, Synthroid$382$35,44557 claims
Johnson & JohnsonXarelto$17$21,64819 claims
MerckJanumet$74$9,01311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Columbia

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →